| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
HAMBURG, Germany & TOKYO—In mid-march, Eppendorf AG and Koki Holdings Co. Ltd. reached an agreement that Eppendorf will acquire Koki’s centrifuge business, including the premium himac brand. The acquisition marks a targeted step by German company Eppendorf AG to expand its centrifuge business, and it says that the deal “solidifies its strong market position as one of the world’s leading makers of high-end centrifuges for the pharma and life-science industries, as well as academic and commercial research.”
 
“We are excited to acquire Koki’s centrifuge business and its premium himac brand. These high-performance products are an ideal fit for Eppendorf’s centrifuges business and high-quality standards,” stated Dr. Peter Fruhstorfer, co-CEO of Eppendorf AG. “With this acquisition, Eppendorf will become a full-line provider of high-performance premium centrifuges on a global level. This gives us access to new customer groups and offers opportunities for further growth.”
 
The centrifuge business is one of Eppendorf’s core businesses, Fruhstorfer continued, which will be sustainably strengthened by the acquisition.
 
“We are excited to have Eppendorf as a partner in acquiring our Centrifuge & Processing (C&P) business, which has held a first-place business track record in Japan for over 65 years,” said Atsushi Morisawa, CEO of Koki Holdings. “With Eppendorf’s investment through this acquisition, I am sure the Koki-originated C&P business will earn an extraordinary positioning in the global market. With that, Koki Holdings will strategically focus on the power tool industry to become the top brand globally.”

Related Topics

Published In

Volume 16 - Issue 4 | April 2020

April 2020

April 2020 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue